Artículos por temáticas

Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders

Arias-Carrión O, Romero-Gutiérrez E, Ortega-Robles E.

NeuroSci. 2025 Oct 21;6(4):107. doi: 10.3390/neurosci6040107.

The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson's Disease: a systematic review

da Silva Chaar Neta R, da Silva Batista C, Machado Palmerim ÉM, Costa Dias HM, Costa Nóbrega KC, de Oliveira CA, Visco DB.

Neuroscience. 2025 Oct 1;584:113-126. doi: 10.1016/j.neuroscience.2025.08.014. Epub 2025 Aug 14.

Potential new drug sources for the treatment of Parkinson's disease: flavonoid O-glycosides

Wang Y, Yang J, Jiang X, Yuan R, Cheng R, Lu N, Gao A, Liu S.

Mol Biol Rep. 2025 Sep 29;52(1):966. doi: 10.1007/s11033-025-10964-8.

Inborn errors of canonical autophagy in neurodegenerative diseases

Freisem D, Hoenigsperger H, Catanese A, Sparrer KMJ.

Hum Mol Genet. 2025 Oct 7;34(R1):R23-R34. doi: 10.1093/hmg/ddae179.

Immunomodulatory natural polysaccharide-based nanoparticles for the treatment of neurodegenerative diseases

Tziveleka LA, Cascione M, Pellegrino P, Bianco A, Leporatti S, De Matteis V.

Ibrain. 2025 May 12;11(3):277-296. doi: 10.1002/ibra.12199. eCollection 2025 Fall.

Retraction notice to "Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial" [Clin Nutr 38 (2019) 1031-1035]

Tamtaji OR, Taghizadeh M, Kakhaki RD, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z.

Clin Nutr. 2025 Oct;53:280. doi: 10.1016/j.clnu.2025.08.012. Epub 2025 Aug 16.

Acetyl-DL-leucine (Tanganil™) in three patients with advanced multiple system atrophy

Oertel WH, Henrich MT, Sittig E, Meyer PT, Strupp M, Janzen A, Geibl FF, Ruppert E.

BMC Neurol. 2025 Oct 2;25(1):407. doi: 10.1186/s12883-025-04451-7.

Septins in the nervous system: from cytoskeletal dynamics to neurological disorders

Alkhanjari RR, Alhajeri MM, Bhamidimarri PM, Alhosani K, Kashir J, Torii T, Hamdan H.

Cell Commun Signal. 2025 Oct 9;23(1):425. doi: 10.1186/s12964-025-02430-6.

The Emergence of a New Healthcare Paradigm for People with Parkinson's Disease in Portugal: Brief Notes on Public and Private Healthcare Systems

Reis Carneiro D, Morgadinho A, Araújo R.

Mov Disord. 2025 Oct;40(10):2275-2276. doi: 10.1002/mds.30292. Epub 2025 Jul 9.

Supports available for apomorphine management: How best to facilitate appropriate usage of apomorphine?

Pirtošek Z.

Parkinsonism Relat Disord. 2025 Sep 30;139 Suppl 1:107934. doi: 10.1016/j.parkreldis.2025.107934. Epub 2025 Jun 25.

Lactate lactylation in neural pathophysiology: Bridging metabolism and neurodegeneration

Cao M, Yin Z, Hu W, Luo Y, Wang Q, Dong P.

Neuroscience. 2025 Oct 15;585:1-13. doi: 10.1016/j.neuroscience.2025.08.048. Epub 2025 Aug 27.

Correction: Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs

Odin P, Tærud C, Samuelsson J, Sabelström E, Lagerlund J, Freilich J, Stelmaszuk MN.

Neurol Ther. 2025 Oct;14(5):1861. doi: 10.1007/s40120-025-00797-9.

MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies-advances and challenges

Azam HMH, Mumtaz M, Rödiger S, Schierack P, Hussain N, Aisha A.

Neurol Sci. 2025 Oct 6. doi: 10.1007/s10072-025-08419-w. Online ahead of print.

Metformin as a potential neuroprotective agent that influence Parkinson's disease

Pal B, Ghatak N, Hossain CM.

Neurol Sci. 2025 Oct;46(10):4805-4818. doi: 10.1007/s10072-025-08370-w. Epub 2025 Aug 4.

[Neurodegenerative Diseases and Isolated REM Sleep Behavior Disorder]

Nishikawa N.

Brain Nerve. 2025 Oct;77(10):1101-1104. doi: 10.11477/mf.188160960770101101.